Adaptive Biotechnologies Corporation $ADPT Shares Sold by Massachusetts Financial Services Co. MA

Massachusetts Financial Services Co. MA lowered its position in Adaptive Biotechnologies Corporation (NASDAQ:ADPT) by 25.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 922,501 shares of the company’s stock after selling 317,124 shares during the period. Massachusetts Financial Services Co. MA’s holdings in Adaptive Biotechnologies were worth $14,981,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of ADPT. Sound Income Strategies LLC acquired a new stake in shares of Adaptive Biotechnologies in the 3rd quarter worth approximately $30,000. Smartleaf Asset Management LLC grew its holdings in shares of Adaptive Biotechnologies by 593.5% in the 3rd quarter. Smartleaf Asset Management LLC now owns 3,939 shares of the company’s stock worth $59,000 after acquiring an additional 3,371 shares during the period. Caxton Associates LLP acquired a new stake in shares of Adaptive Biotechnologies in the 1st quarter worth approximately $93,000. Quadrant Capital Group LLC acquired a new stake in shares of Adaptive Biotechnologies in the 3rd quarter worth approximately $133,000. Finally, Keybank National Association OH acquired a new stake in shares of Adaptive Biotechnologies in the 3rd quarter worth approximately $155,000. Institutional investors and hedge funds own 99.17% of the company’s stock.

Insider Activity at Adaptive Biotechnologies

In other Adaptive Biotechnologies news, insider Harlan S. Robins sold 470,266 shares of the stock in a transaction on Wednesday, March 11th. The stock was sold at an average price of $13.17, for a total transaction of $6,193,403.22. Following the transaction, the insider owned 1,522,058 shares of the company’s stock, valued at $20,045,503.86. This represents a 23.60% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, COO Julie Rubinstein sold 141,583 shares of the stock in a transaction on Wednesday, March 11th. The stock was sold at an average price of $13.29, for a total value of $1,881,638.07. Following the transaction, the chief operating officer directly owned 516,610 shares in the company, valued at approximately $6,865,746.90. This represents a 21.51% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 2,479,941 shares of company stock worth $35,758,311. Company insiders own 6.40% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on ADPT shares. Piper Sandler set a $21.00 price target on Adaptive Biotechnologies in a report on Friday, February 6th. Wall Street Zen lowered Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a research note on Saturday, March 7th. Guggenheim upped their target price on Adaptive Biotechnologies from $20.00 to $21.00 and gave the company a “buy” rating in a research note on Monday, January 26th. JPMorgan Chase & Co. upped their target price on Adaptive Biotechnologies from $20.00 to $21.00 and gave the company an “overweight” rating in a research note on Friday, February 6th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Adaptive Biotechnologies in a research note on Friday, February 6th. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $18.25.

Adaptive Biotechnologies Stock Performance

ADPT stock opened at $14.08 on Friday. Adaptive Biotechnologies Corporation has a 1 year low of $6.77 and a 1 year high of $20.76. The stock’s 50 day moving average price is $14.69 and its 200 day moving average price is $15.98. The firm has a market cap of $2.17 billion, a P/E ratio of -35.20 and a beta of 2.29.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its earnings results on Thursday, February 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.10. Adaptive Biotechnologies had a negative return on equity of 46.68% and a negative net margin of 21.48%.The firm had revenue of $71.68 million for the quarter, compared to analyst estimates of $59.38 million. During the same quarter in the prior year, the company earned ($0.23) EPS. Adaptive Biotechnologies’s revenue was up 51.0% on a year-over-year basis. On average, research analysts predict that Adaptive Biotechnologies Corporation will post -0.92 earnings per share for the current year.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.